Cardiometabolic Inflammation in Vitiligo: Association with Metabolic Syndrome and Inflammatory Biomarkers
Open Access
- 19 October 2026
- journal article
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 16 (4) , 7601
Abstract
Background: Vitiligo, previously considered a localized skin disease, is now regarded as a systemic condition due to its association with autoimmune and metabolic abnormalities. The relationship between metabolic syndrome (MetS) and vitiligo is not clearly established. Chronic inflammation and oxidative stress may also contribute to inflammation-related cardiometabolic processes, even in the absence of MetS. Objectives: To investigate MetS components and inflammatory biomarkers (TNF-α, IL-6, GDF-15, and CCL-7) in patients with vitiligo without comorbidities and to compare the findings with healthy individuals. Methods: In this case–control study, 43 patients with vitiligo and 43 frequency-matched controls (18–65 years) were included. Participants with systemic diseases, smoking or alcohol use, or medications affecting metabolic parameters were excluded. Disease severity and activity were assessed using VASI, BSA, and VIDA scores. Anthropometric data, blood pressure, and laboratory parameters were recorded. Serum biomarker levels were measured by ELISA. Results: The two groups were similar in terms of age and sex. Systolic blood pressure was higher in the vitiligo group (P=0.011), whereas other metabolic parameters and MetS prevalence were comparable. Longer disease duration was associated with the presence of MetS (P=0.008). TNF-α, IL-6, GDF-15, and CCL-7 levels were significantly higher in patients than controls. Among these, GDF-15 and CCL-7 were associated with disease activity, while TNF-α and IL-6 were not. Multivariable regression analysis demonstrated that GDF-15 remained independently associated with vitiligo after adjusting for age, sex, and BMI, whereas the association with CCL-7 was no longer statistically significant. Conclusion: MetS prevalence was not increased in vitiligo; however, elevated inflammatory biomarkers may reflect inflammation-related cardiometabolic processes. After adjusting for age, sex, and BMI, GDF-15 remained independently associated with vitiligo, whereas the association with CCL-7 was no longer statistically significant.Keywords
This publication has 27 references indexed in Scilit:
- Vitiligo and the metabolic syndrome: clarifying the inconsistent relationship by a large-scale population-based studyArchives of Dermatological Research, 2024
- Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional studyAnais Brasileiros de Dermatologia, 2020
- Predominant role of innate pro-inflammatory cytokines in vitiligo diseaseArchives of Dermatological Research, 2019
- Vitiligo: An Update on Pathophysiology and Treatment OptionsAmerican Journal of Clinical Dermatology, 2017
- VitiligoThe Lancet, 2015
- Inflammation as a link between obesity, metabolic syndrome and type 2 diabetesDiabetes Research and Clinical Practice, 2014
- Metabolic SyndromeEndocrinology and Metabolism Clinics of North America, 2014
- Monocyte chemotactic protein-3 induces human coronary smooth muscle cell proliferationAtherosclerosis, 2011
- The metabolic syndrome—a new worldwide definitionThe Lancet, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001